Archive: Company News
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
– Two renowned oncology experts to support the development of Thermosome’s clinical candidate THE001
Thermosome, a drug development company specializing in targeted tumor therapies, today announced the appointment of Dr. Frank Hermann, MD, as Chief Medical Officer (CMO) and the expansion of its Clinical Advisory Board with the addition of Prof. Alessandro Gronchi, MD.
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
— Presentation at the World Vaccine Congress West Coast2023
— EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodies
— Novel in-vitro data support preclinical proof-of-concept data
EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, has presented new in vitro data of its EBV-vaccine candidate EBV-001 at the World Vaccine Congress West Coast 2023 (Nov. 27-30, 2023) in Santa Clara, CA (USA). The presentation by EBViously’s designated COO Sebastian Goy was held on Thursday, November 30, 2023. Read more…
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
— Funding up to Euro 1.8 million awarded by German Federal Ministry of Education and Research BMBF
Ebenbuild, a company developing personalized, AI-driven virtual lungs to support clinical decisions and digital clinical trials, today announced its participation in the research project Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC) in collaboration with the University Hospital Schleswig-Holstein, Augsburg University Hospital, University Hospital Carl Gustav Carus Dresden, University Hospital RWTH Aachen and University Medical Center Mannheim.
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
– Phase I data show safety and tolerability at clinically significant dose levels
– New class of anti-infectives to treat infections with Gram-negative bacteria
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6.